Immuneering Corporation Operating Lease, Right-of-Use Asset, Amortization Expense
Immuneering Corporation (IMRX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $185.90 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-05
- Immuneering Corporation operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $94.14K, a 10.48% increase year-over-year.
- Immuneering Corporation operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $91.76K, a 10.31% increase year-over-year.
- Immuneering Corporation operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $89.44K, a 10.14% increase year-over-year.
- Immuneering Corporation operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $87.27K, a 9.95% increase year-over-year.
- Immuneering Corporation operating lease, right-of-use asset, amortization expense for fiscal 2025 was $345.10K, a 5.09% increase from fiscal 2024.
- Immuneering Corporation operating lease, right-of-use asset, amortization expense for fiscal 2024 was $328.38K, a 20.31% decline from fiscal 2023.
- Immuneering Corporation operating lease, right-of-use asset, amortization expense for fiscal 2023 was $412.06K, a 20.69% decline from fiscal 2022.
- Immuneering Corporation operating lease, right-of-use asset, amortization expense for fiscal 2022 was $519.54K, a 357.32% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $94.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $185.90K 10-Q · filed 2026-08-05 | $275.34K derived: sum of 3 quarters · filed 2026-08-05 | $362.61K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $91.76K 10-Q · filed 2026-05-15 | $181.20K derived: sum of 2 quarters · filed 2026-05-15 | $268.48K derived: sum of 3 quarters · filed 2026-05-15 | $353.68K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $89.44K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $176.72K derived: sum of 2 quarters · filed 2026-03-06 | $261.92K derived: sum of 3 quarters · filed 2026-08-05 | $345.10K 10-K · filed 2026-03-06 |
| 2025-09-30 | $87.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $172.48K derived: sum of 2 quarters · filed 2026-08-05 | $255.66K 10-Q · filed 2025-11-12 | $336.87K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $85.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $168.39K 10-Q · filed 2026-08-05 | $249.60K derived: sum of 3 quarters · filed 2026-08-05 | $328.98K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $83.18K 10-Q · filed 2026-05-15 | $164.40K derived: sum of 2 quarters · filed 2026-05-15 | $243.77K derived: sum of 3 quarters · filed 2026-05-15 | $321.40K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $81.21K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $160.59K derived: sum of 2 quarters · filed 2026-03-06 | $238.22K derived: sum of 3 quarters · filed 2026-03-06 | $328.38K 10-K · filed 2026-03-06 |
| 2024-09-30 | $79.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $157.01K derived: sum of 2 quarters · filed 2025-11-12 | $247.16K 10-Q · filed 2025-11-12 | $335.31K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $77.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $167.79K 10-Q · filed 2025-08-13 | $255.93K derived: sum of 3 quarters · filed 2025-08-13 | $366.11K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $90.16K 10-Q · filed 2025-05-05 | $178.30K derived: sum of 2 quarters · filed 2025-05-05 | $288.47K derived: sum of 3 quarters · filed 2025-05-05 | $396.42K derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $88.14K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $198.32K derived: sum of 2 quarters · filed 2025-03-20 | $306.27K derived: sum of 3 quarters · filed 2025-03-20 | $412.06K 10-K · filed 2025-03-20 |
| 2023-09-30 | $110.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $218.12K derived: sum of 2 quarters · filed 2024-11-13 | $323.91K 10-Q · filed 2024-11-13 | $429.01K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $107.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $213.74K 10-Q · filed 2024-08-06 | $318.83K derived: sum of 3 quarters · filed 2024-08-06 | $447.98K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $105.79K 10-Q · filed 2024-05-07 | $210.88K derived: sum of 2 quarters · filed 2024-05-07 | $340.02K derived: sum of 3 quarters · filed 2024-05-07 | $480.51K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $105.10K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $234.24K derived: sum of 2 quarters · filed 2024-03-01 | $374.72K derived: sum of 3 quarters · filed 2024-03-01 | $519.54K 10-K · filed 2024-03-01 |
| 2022-09-30 | $129.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $269.62K derived: sum of 2 quarters · filed 2023-11-09 | $414.44K 10-Q · filed 2023-11-09 | $452.13K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $140.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $285.30K 10-Q · filed 2023-08-03 | $322.99K derived: sum of 3 quarters · filed 2023-08-03 | $348.57K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $144.82K 10-Q · filed 2023-05-04 | $182.50K derived: sum of 2 quarters · filed 2023-05-04 | $208.09K derived: sum of 3 quarters · filed 2023-05-04 | $233.40K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $37.68K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $63.27K derived: sum of 2 quarters · filed 2023-03-06 | $88.58K derived: sum of 3 quarters · filed 2023-03-06 | $113.61K 10-K · filed 2023-03-06 |
| 2021-09-30 | $25.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $50.90K derived: sum of 2 quarters · filed 2022-11-10 | $75.92K 10-Q · filed 2022-11-10 | $100.68K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $25.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $50.33K 10-Q · filed 2022-08-10 | $75.09K derived: sum of 3 quarters · filed 2022-08-10 | $85.32K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $25.03K 10-Q · filed 2022-05-10 | $49.79K derived: sum of 2 quarters · filed 2022-05-10 | $60.01K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $24.76K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $34.98K derived: sum of 2 quarters · filed 2022-03-10 | $54.98K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $10.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $30.22K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $19.99K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |